Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Operating Expenses (2023 - 2025)

CG Oncology's Operating Expenses history spans 3 years, with the latest figure at $51.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 32.51% year-over-year to $51.0 million; the TTM value through Dec 2025 reached $194.8 million, up 68.23%, while the annual FY2025 figure was $194.8 million, 68.23% up from the prior year.
  • Operating Expenses reached $51.0 million in Q4 2025 per CGON's latest filing, down from $52.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $52.8 million in Q3 2025 to a low of $9.9 million in Q1 2023.
  • Average Operating Expenses over 3 years is $30.5 million, with a median of $27.2 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: soared 131.95% in 2024, then skyrocketed 32.51% in 2025.
  • A 3-year view of Operating Expenses shows it stood at $19.4 million in 2023, then soared by 98.93% to $38.5 million in 2024, then skyrocketed by 32.51% to $51.0 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Operating Expenses are $51.0 million (Q4 2025), $52.8 million (Q3 2025), and $48.7 million (Q2 2025).